Hypermethylation of the VTRNA1-3 Promoter is Associated with Poor Outcome in Lower Risk Myelodysplastic Syndrome Patients

Author： Søgaard Helbo Alexandra   Treppendahl Marianne   Aslan Derya   Dimopoulos Konstantinos   Nandrup-Bus Cecilie   Holm Mette Skov   Andersen Mette Klarskov   Liang Gangning   Kristensen Lasse Sommer   Grønbæk Kirsten  

Publisher： MDPI

E-ISSN： 2073-4425|6|4|977-990

ISSN： 2073-4425

Source： Genes, Vol.6, Iss.4, 2015-10, pp. : 977-990

Access to resources Favorite

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Hypermethylation of MAPK13 Promoter in Oesophageal Squamous Cell Carcinoma Is Associated with Loss of p38δ MAPK Expression

By O′Callaghan Carol   Fanning Liam J.   Barry Orla P.  

Cancers, Vol. 7, Iss. 4, 2015-10 ,pp. : 2124-2133

MDPI

Access to resources Recommend Favorite

Comparison of clinical efficacy between decitabine combined with half the amount of CAG regimen with CAG regimen alone in patients with inermediate to high-risk myelodysplastic syndrome

By  

Bio Web of conference, Vol. 8, Iss. issue, 2017-01 ,pp. : 01024-01024

Edp Sciences

Access to resources Recommend Favorite

FERMT1 promoter mutations in patients with Kindler syndrome

By  

CLINICAL GENETICS, Vol. 88, Iss. 3, 2015-09 ,pp. : 248-254

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hereditary Predispositions to Myelodysplastic Syndrome

By Bannon Sarah A.   DiNardo Courtney D.  

International Journal of Molecular Sciences, Vol. 17, Iss. 6, 2016-05 ,pp. : 838-838

MDPI

Access to resources Recommend Favorite

Immune Mechanisms in Myelodysplastic Syndrome

By Glenthøj Andreas   Ørskov Andreas Due   Hansen Jakob Werner   Hadrup Sine Reker   O’Connell Casey   Grønbæk Kirsten  

International Journal of Molecular Sciences, Vol. 17, Iss. 6, 2016-06 ,pp. : 944-944

MDPI

Access to resources Recommend Favorite